Recludix Pharma to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s management will participate in two investor conferences in November.

• Guggenheim Second Annual Healthcare Innovation Conference in Boston, MA
  • Presentation on Monday, November 10, 2025, at 1:30 p.m. ET
• Stifel 2025 Healthcare Conference in New York, NY
  • Presentation on Tuesday, November 11, 2025, at 11:20 a.m. ET

To access the live and archived webcasts of the presentations, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events. The archived webcasts will be available for 30 days following each presentation.

About Recludix
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced program is focused on STAT6 (signal transducer and activator of transcription 6) where abnormal activation is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria. The company has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor, and it is planning to submit an Investigational New Drug application for its STAT6 inhibitor REX-8756 in 2025. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company. For more information, please visit the company’s website at https://recludixpharma.com.

Recludix Contacts
Matt Caldemeyer
Chief Business Officer
[email protected]

Alexandra Santos
[email protected]

Aljanae Reynolds
[email protected]

You May Also Be Interested In

• Crypto News Today: AlphaPepe Presale Nears Sellout With 11,000 Buyers While XRP Price Prediction Eyes $10
• Mark-Dana Corporation Opens Lost Oaks, New Affordable Housing Community in North Central Houston
• FRONTERA ANNOUNCES SECOND QUARTER 2026 RESULTS